Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Efficacy and Safety of Atezolizumab Monotherapy or Combined Therapy with Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Author(s): Mina Alimohammadi, Fatemeh Faramarzi, Alireza Mafi, Tahoora Mousavi, Ali Rahimi, Hamed Mirzaei* and Zatollah Asemi*

Volume 29, Issue 31, 2023

Published on: 26 October, 2023

Page: [2461 - 2476] Pages: 16

DOI: 10.2174/0113816128270102231016110637

Price: $65

Abstract

Introduction: Several successful attempts have been recorded with PD-L1 blockade via atezolizumab monotherapy or combination therapy with chemotherapy in patients with metastatic triple-negative breast cancer (mTNBC). Due to the lack of a large-scale study, we present a meta-analysis aimed at evaluating the safety and efficacy of this promising strategy in patients with mTNBC.

Methods: A comprehensive literature search was conducted using electronic databases to identify eligible RCTs. Twelve studies, including 2479 mTBNC patients treated with atezolizumab monotherapy or in combination with chemotherapy, were included up to January 2022. The PRISMA checklist protocol and the I2 statistic were applied for quality assessment and heterogeneity tests of the selected trials, respectively. Fixed and random-effects models were estimated based on the heterogeneity tests, and statistical analysis was performed using CMA.

Results: Our pooled findings demonstrated that the median overall survival (OS) and progression-free survival (PFS) were 16.526 and 5.814 months in mTNBC patients, respectively. Furthermore, when comparing efficacy indicators between PD-L1-positive and PD-L1-negative groups, mTNBC patients with PD-L1 had better OS, PFS, and ORR than PD-L1-negative patients. Also, the immune-related adverse event incident for alopecia was higher (51.9%) than other complications across atezolizumab therapy.

Conclusion: Moreover, the pooled analysis indicated that the overall rate of lung metastasis following atezolizumab therapy was 42.8%, which was higher than the rates of metastasis in bone (26.9%), brain (5.4%), and lymph node (6.5%). Atezolizumab showed a manageable safety profile and had promising and durable anti-tumor efficacy in TMBC patients. Higher PD-L1 expression may be closely correlated with better clinical efficacy.

« Previous Next »
[1]
Vinay DS, Kwon BS. Harnessing immune checkpoints for cancer therapy. Immunotherapy 2018; 10(14): 1265-84.
[http://dx.doi.org/10.2217/imt-2017-0168] [PMID: 30326786]
[2]
Eika S, Peng L, Renato B, Nicholas R, Ming Y, Yaohe W. Immune checkpoint inhibitors in cancer therapy. J Biomed Res 2018; 32(5): 317-26.
[http://dx.doi.org/10.7555/JBR.31.20160168] [PMID: 28866656]
[3]
Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: The immunotherapy era. BMC Med 2019; 17(1): 90.
[http://dx.doi.org/10.1186/s12916-019-1326-5] [PMID: 31068190]
[4]
Muddu V, Boindala N. Immunotherapy for triple-negative breast cancer: Time to pause? Cancer Rese Statist Treat 2022; 5(1): 182.
[http://dx.doi.org/10.4103/crst.crst_42_22]
[5]
Dixon-Douglas J, Loibl S, Denkert C, Telli M, Loi S. Integrating immunotherapy into the treatment landscape for patients with triple-negative breast cancer Am Soc Clin Oncol Educ 2022; 42(42): 47-59.
[http://dx.doi.org/10.1200/EDBK_351186] [PMID: 35649211]
[6]
Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014; 2(4): 361-70.
[http://dx.doi.org/10.1158/2326-6066.CIR-13-0127] [PMID: 24764583]
[7]
Shah NJ, Kelly WJ, Liu SV, Choquette K, Spira A. Product review on the Anti-PD-L1 antibody atezolizumab Taylor Francis 2018.
[http://dx.doi.org/10.1080/21645515.2017.1403694]
[8]
Adams S, Diamond JR, Hamilton E, et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: A phase 1b clinical trial. JAMA Oncol 2019; 5(3): 334-42.
[http://dx.doi.org/10.1001/jamaoncol.2018.5152] [PMID: 30347025]
[9]
Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. JAMA Oncol 2019; 5(1): 74-82.
[http://dx.doi.org/10.1001/jamaoncol.2018.4224] [PMID: 30242306]
[10]
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379(22): 2108-21.
[http://dx.doi.org/10.1056/NEJMoa1809615] [PMID: 30345906]
[11]
Kwapisz D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother 2021; 70(3): 607-17.
[http://dx.doi.org/10.1007/s00262-020-02736-z] [PMID: 33015734]
[12]
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19(1): 40-50.
[http://dx.doi.org/10.1016/S1470-2045(17)30904-X] [PMID: 29233559]
[13]
García-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-infiltrating lymphocytes in triple negative breast cancer: The future of immune targeting. Clin Med Insights Oncol 2016; 10 (Suppl. 1): 31-9.
[http://dx.doi.org/10.4137/CMO.S34540]
[14]
Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: A systematic review. JAMA Oncol 2016; 2(10): 1354-60.
[http://dx.doi.org/10.1001/jamaoncol.2016.1061] [PMID: 27355489]
[15]
Abraham J, Varma R, Wright M, Kruse M. Immune checkpoint inhibition in early-stage triple-negative breast cancer. Expert Rev Anticancer Ther 2022; 22(11): 1225-38.
[16]
Tornincasa A, Canino F, Trudu L, et al. Atezolizumab-related sarcoidosis-like reaction in early breast cancer patient: Know it to diagnose it: A case report with review of the literature. Arch Clin Med Case Rep 2022; 6(4): 611-2.
[http://dx.doi.org/10.26502/acmcr.96550528]
[17]
Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol 2019; 30(2): 219-35.
[http://dx.doi.org/10.1093/annonc/mdy551] [PMID: 30608567]
[18]
Emens LA, Molinero L, Loi S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: Biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst 2021; 113(8): 1005-16.
[http://dx.doi.org/10.1093/jnci/djab004] [PMID: 33523233]
[19]
Hussaini S, Chehade R, Boldt RG, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors: A systematic review and meta-analysis. Cancer Treat Rev 2021; 92: 102134.
[http://dx.doi.org/10.1016/j.ctrv.2020.102134] [PMID: 33302134]
[20]
Fujii T, Naing A, Rolfo C, Hajjar J. Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol 2018; 130: 108-20.
[http://dx.doi.org/10.1016/j.critrevonc.2018.07.010] [PMID: 30196907]
[21]
Zou Y, Zou X, Zheng S, et al. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: A systematic review and meta-analysis Ther Adv Med Oncol 2020; 12
[http://dx.doi.org/10.1177/1758835920940928] [PMID: 32874208]
[22]
Latif F, Bint Abdul Jabbar H, Malik H, et al. Atezolizumab and pembrolizumab in triple-negative breast cancer: A meta-analysis. Expert Rev Anticancer Ther 2022; 22(2): 229-35.
[http://dx.doi.org/10.1080/14737140.2022.2023011] [PMID: 34949142]
[23]
Sharmni Vishnu K, Win TT, Aye SN, Basavaraj AK. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: A meta-analysis on their efficacy and safety. BMC Cancer 2022; 22(1): 1139.
[http://dx.doi.org/10.1186/s12885-022-10225-y] [PMID: 36335316]
[24]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339(jul21 1): b2700.
[http://dx.doi.org/10.1136/bmj.b2700] [PMID: 19622552]
[25]
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials BMJ 2011; 343(oct18 2): d5928.
[http://dx.doi.org/10.1136/bmj.d5928] [PMID: 22008217]
[26]
Ameri A, Tavakoli-Far B, Rostami M, et al. Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer. Int Immunopharmacol 2022; 113(Pt A): 109334.
[http://dx.doi.org/10.1016/j.intimp.2022.109334] [PMID: 36327869]
[27]
Zhang X, Ge X, Jiang T, Yang R, Li S. Research progress on immunotherapy in triple-negative breast cancer. Review. Int J Oncol 2022; 61(2): 95.
[http://dx.doi.org/10.3892/ijo.2022.5385] [PMID: 35762339]
[28]
Abdou Y, Goudarzi A, Yu JX, Upadhaya S, Vincent B, Carey LA. Immunotherapy in triple negative breast cancer: Beyond checkpoint inhibitors. npj. Breast Cancer 2022; 8(1): 1-10.
[PMID: 35013314]
[29]
Ovcaricek T, Dobovisek L, Gasljevic G, Stefanovski D, Borstnar S. PD-L1 immune cell expression levels and clinical outcomes in advanced triple-negative breast cancer treated with atezolizumab. American Society of Clinical Oncology 2022.
[http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.e13066]
[30]
Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 2018; 6(1): 39.
[http://dx.doi.org/10.1186/s40425-018-0349-3] [PMID: 29769148]
[31]
Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol 2022; 33(5): 534-43.
[http://dx.doi.org/10.1016/j.annonc.2022.02.004] [PMID: 35182721]
[32]
Loibl S, Untch M, Burchardi N, et al. Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J Clin Oncol 2018; 36(15) (Suppl.): 104.
[http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.104]
[33]
Molinero L, Emens LA, Goldstein LD, et al. Mechanisms of action and acquired resistance to atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC). American Society of Clinical Oncology 2022.
[http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.1078]
[34]
Schmid P, Adams S, Rugo HS, et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo)+ nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). American Society of Clinical Oncology 2019.
[35]
Khosravi-Shahi P, Cabezón-Gutiérrez L, Custodio-Cabello S. Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol 2018; 14(1): 32-9.
[http://dx.doi.org/10.1111/ajco.12748] [PMID: 28815913]
[36]
Mamounas E, Bandos H, Lembersky B, et al. Abstract S1-05: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. Cancer Res 2017; 77: S1-5.
[http://dx.doi.org/10.1158/1538-7445.SABCS16-S1-05]
[37]
He R, Yuan X, Chen Z, Zheng Y. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. Int Immunopharmacol 2022; 113(Pt B): 109444.
[http://dx.doi.org/10.1016/j.intimp.2022.109444] [PMID: 36402069]
[38]
Page DB, Bear H, Prabhakaran S, et al. Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer 2019; 5(1): 34.
[http://dx.doi.org/10.1038/s41523-019-0130-x] [PMID: 31602395]
[39]
Aran D, Klein-Brill A, Fisch MJ, Amar-Farkash S. Real-world data comparing atezolizumab plus taxane therapy versus taxane alone as first-line treatment of metastatic triple-negative breast cancer patients in the United States American Society of Clinical Oncology 2022.
[http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.e18767]
[40]
Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36(17): 1714-68.
[http://dx.doi.org/10.1200/JCO.2017.77.6385] [PMID: 29442540]
[41]
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5(1): 95.
[http://dx.doi.org/10.1186/s40425-017-0300-z] [PMID: 29162153]
[42]
Brufsky A, Kim SB, Zvirbule Ž, et al. A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): Primary analysis. Ann Oncol 2021; 32(5): 652-60.
[http://dx.doi.org/10.1016/j.annonc.2021.01.065] [PMID: 33539944]
[43]
Narayan P, Wahby S, Gao JJ, et al. FDA approval summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic tnbc whose tumors express PD-L1. Clin Cancer Res 2020; 26(10): 2284-9.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-3545] [PMID: 32001481]
[44]
Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 2021; 32(8): 994-1004.
[http://dx.doi.org/10.1016/j.annonc.2021.05.801] [PMID: 34219000]
[45]
Wang H, Ma H, Sové RJ, Emens LA, Popel AS. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. J Immunother Cancer 2021; 9(2): e002100.
[http://dx.doi.org/10.1136/jitc-2020-002100] [PMID: 33579739]
[46]
Iwata H, Inoue K, Kaneko K, et al. Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130). Jpn J Clin Oncol 2019; 49(12): 1083-91.
[http://dx.doi.org/10.1093/jjco/hyz135] [PMID: 31612909]
[47]
Adams S, Diamond JR, Hamilton EP, et al. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). American Society of Clinical Oncology 2016.
[http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.1009]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy